Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study

The Lancet Gastroenterology & Hepatology - Tập 4 - Trang 771-780 - 2019
Emily D Bethea1,2,3, Kerry Gaj3,4, Jenna L Gustafson2,3, Andrea Axtell1,3,5, Taylor Lebeis1,3,4, Mark Schoenike4, Karen Turvey3,4, Erin Coglianese1,3,4, Sunu Thomas1,3,4, Christopher Newton-Cheh1,3,4, Nasrien Ibrahim1,3,4, William Carlson1,3,4, Jennifer E Ho1,3,4, Ravi Shah1,3,4, Matthew Nayor1,3,4, Thais Gift6, Sarah Shao6, Amanda Dugal6, James Markmann1,3,7, Nahel Elias1,3,7
1Harvard Medical School, Boston, MA, USA
2Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA
3Massachusetts General Hospital Transplant Center, Massachusetts General Hospital, Boston, MA, USA
4Cardiology Division, Massachusetts General Hospital, Boston, MA, USA
5Cardiothoracic Surgery Division, Massachusetts General Hospital, Boston, MA, USA
6Division of Pharmacy, Massachusetts General Hospital, Boston, MA, USA
7Transplant Surgery Division, Massachusetts General Hospital, Boston, MA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Gastroenterology & Hepatology

Tập 4

771-780

Thông tin tác giả